Education, Science, Technology, Innovation and Life
Open Access
Sign In

Evaluation of Renal Dysfunction in Heart Failure Patients Based on Serum Levels of Gal-3 and IL-6

Download as PDF

DOI: 10.23977/medbm.2024.020206 | Downloads: 20 | Views: 853

Author(s)

Jianlong Li 1, Zhe Li 2,3, Haiming Li 1, Yichao Zhang 1

Affiliation(s)

1 Department of Cardiology, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China
2 Department of Nephrology, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China
3 Key Laboratory of Bone Metabolism and Physiology in Chronic Kidney Disease of Hebei Province, Baoding, Hebei, 071000, China

Corresponding Author

Zhe Li

ABSTRACT

The objective of this study is to investigate the serum concentrations of Galectin-3 (Gal-3) and interleukin-6 (IL-6) in individuals with heart failure (HF) and to assess their relationship with markers of renal function. Between September 2021 and September 2023, 230 consecutive patients diagnosed with HF at the cardiovascular department of our institution were recruited. Venous blood samples were obtained from each participant to determine the serum levels of Gal-3 and IL-6. A subsequent analysis was conducted to explore the correlation between these biomarkers and renal function parameters. Our findings revealed a notable escalation in Gal-3 and IL-6 levels in serum as the cardiac functional grading increased. Additionally, a significant positive association was observed between these two biomarkers and crucial renal function indicators, specifically serum creatinine and urea nitrogen. Consequently, the serum levels of Gal-3 and IL-6 can serve as valuable reference markers for evaluating the renal status of HF patients. Monitoring these biomarkers enables clinicians to make a more informed assessment of renal function in HF patients, ultimately leading to the development of more tailored treatment strategies for these individuals.

KEYWORDS

Heart failure; Renal dysfunction; Galectin-3 (gal-3); Interleukin-6 (IL-6); Biomarker

CITE THIS PAPER

Jianlong Li, Zhe Li, Haiming Li, Yichao Zhang, Evaluation of Renal Dysfunction in Heart Failure Patients Based on Serum Levels of Gal-3 and IL-6. MEDS Basic Medicine (2024) Vol. 2: 34-38. DOI: http://dx.doi.org/10.23977/medbm.2024.020206.

REFERENCES

[1] Wang B, Bai Y, Yao Z, et al. A Multi-Task Neural Network Architecture for Renal Dysfunction Prediction in Heart Failure Patients with Electronic Health Records [J]. IEEE Access, 2019, 7:178392-178400.
[2] Juan Martínez-Milla, Marcelino Cortés García, Palfy J A, et al. Beta-blocker therapy in elderly patients with renal dysfunction and heart failure[J]. Journal of Geriatric Cardiology, 2021, 18(1):20-29.
[3] Lan J, Wang L, Wang S, et al. The correlation between serum ANG-2, Gal-3 and BNP levels and cardiac function in patients with chronic heart failure [J]. Acta Medica Mediterranea, 2020, 36(3):1599-1603.
[4] Lashkul D A. Impact of statins on long-term prognosis in patients with ischemic chronic heart failure with renal dysfunction [J]. Zaporozhye Medical Journal, 2020, 22(2):148-153.
[5] Costa Y C, Delfino F A, Trevisani H, et al. Estimation of Kinetic Glomerular Filtration Rate in Patients with Decompensated Heart Failure[J]. Argentine Journal of Cardiology, 2019, 87:137-145.
[6] Zaharie M, Carstea D, Streba C T, et al. Renal Dysfunction - a Possible Marker of Severity of Heart Failure[J]. Revista de Chimie -Bucharest- Original Edition-, 2018, 69(6):1435-1440. 
[7] Kotecha D, Gill S K, Flather M D, et al. Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure[J]. Journal of the American College of Cardiology, 2019, 74(23):2893-2904.

Downloads: 1586
Visits: 78210

Sponsors, Associates, and Links


All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.